Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Abstracts arising from participation in ISN Programs may be eligible to compete for certain ISN Program Awards. Please indicate if you have taken part in any of the official ISN Programs mentioned hereafter, and your abstract is associated with your participation:
State the purpose of the study, describe the method, summarize the results presenting sufficient details to support the conclusions, and give the conclusions reached (it is not acceptable to state 'The results will be discussed'). Use numerals for numbers and only very well-known abbreviations e.g., ml, Osm, GFR. If you must use other abbreviations, please explain them the first time they appear. Limit the use of symbols (i.e., use M or F to indicate Male and Female instead of the symbol font). Do not identify yourself or your institution in the text.
You may use up to 3,400 characters. Spaces are included in the character count (tables and graphs do not count as characters if inserted as an image). Abstract authors/co-authors’ names and affiliations, and keywords do not count towards the 3,400-character allowance.
Images must be in JPEG or PNG format (uploaded images cannot exceed 640w x 480h pixels and 1.5 MB).
The abstract should be following this structure: Introduction, Methods, Results and Conclusions.
Chronic pain is a common symptom for patients with Chronic Kidney Disease (CKD) and reduces health-related quality of life. Loin pain is a predominant feature in certain rare kidney diseases such as Autosomal Dominant Polycystic Kidney Disease. Little is known about loin pain in other rare kidney diseases, including whether loin pain is associated with reduced kidney function, or disease progression. In this questionnaire study we describe the severity and frequency of loin pain in RaDaR participants, and examine associations between loin pain and CKD progression and age at kidney failure.
RaDaR participants were invited by email to complete an online questionnaire between 5/3/24-3/6/24. Responses were collated on the JISC online platform. Participants were asked to indicate whether and when they experienced loin pain, analgesic usage, and complete the Short Form McGill Pain Questionnaire (SF-MPQ-2). Responses were linked to RaDaR demographic data, validated data from the UK Renal Registry on Kidney Replacement Therapy (KRT) initiation, and renal unit laboratory data. Responses were examined individually and by disease type (non-inflammatory, glomerular, cystic, metabolic, tubular, other disorders and Alport syndrome). Baseline characteristics were compared between patients with and without loin pain. Multivariable logistic regression was used to examine associations between loin pain and age, Sex, Ethnicity, Body Mass Index (BMI), Index of Multiple Deprivation Quintile (IMD, an area level measure of deprivation), disease type (baseline=non-inflammatory disorders), and CKD stage/KRT status. Linear regression was used to fit a straight line through each patient’s mean eGFR values for each 3 month period of follow up post diagnosis to determine annualised eGFR slopes for patients with and without loin pain.
3867/16431 patients from 31 rare disease groups completed the questionnaire (24% response rate). Loin pain was reported by 62% of respondents, 23% historically and 39% recently (Table1). Respondents who were female (aOR 1.62, 95% CI [1.38-1.90], p<0.001), had a higher BMI (BMI >40, aOR 2.2, [1.39-3.72], p<0.0001), were from more socially deprived areas (IMD Quintile 1-most deprived, aOR 1.75 [1.29-2.37], p<0.001), and had metabolic or cystic kidney disease (aOR 6.1 [2.10-17.7], p<0.001 and aOR 1.72 [1.37-2.15], p<0.001, respectively) had higher odds of loin pain. Ethnicity and CKD stage/KRT status were not associated with increased odds of loin pain (aOR 0.92 [0.80-1.05] p=0.25 and aOR 1.02 [0.98-1.06], p=0.39 respectively). Pain was most frequently reported as aching (79%). Median pain rating index derived from the SF-MPQ-2 was 29, IQR [11-62] for all respondents, and varied by disease type (non-inflammatory disorders median 4, IQR [0-32], metabolic disease 30.5, [9.5-77.5]). 41% of respondents experiencing loin pain used analgesia at least weekly. 4% used strong opioids. Mean annualised eGFR slope over total follow up was -2.8 ml/min/1.73m2/yr (SD 9.0) for participants with loin pain, and -1.9 ml/min/1.73m2/yr (SD 8.4) for those without (p=0.03).
Loin pain is common in rare kidney diseases: > 60% of participants had experienced loin pain. Loin pain was not associated with CKD stage/KRT status, suggesting it may be related to disease aetiology rather than simply reduced kidney function, but was associated with faster eGFR decline.
Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in KIR publisher’s (Elsevier) AI policy for authors.
Authors should disclose in their abstract the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.
Disclosure instructions: Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their abstract, in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.
This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.
The deadline abstract presenters must register by is November 6, 2024, to have their abstract published in Kidney International Reports® and presented at WCN.
A cancellation of registration after the registration deadline will result in no publication and presentation of the abstract unless the abstract presenter is replaced by a fully registered delegate. Please note that in case you receive a grant or sponsorship support after registering and wish to cancel/refund, the WCN cancellation policy will apply.
In the event the presenting author cannot attend, and they wish to change to a new presenting author, the original presenting author must communicate this information to the Abstract team (abstractswcn@theisn.org) to confirm that the new presenting author is registered. Failure to do so will result in the withdrawal of the abstract.
Abstract presenters must register using the same email, if they fail to do so and do not communicate the change of email to the Abstract team, the abstract might not be published in Kidney International Reports® or presented onsite. WCN organizers will not be held responsible for non-publication.